Cargando…

Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor

Patient-derived xenografts provide significant advantages over long-term passage cell lines when investigating efficacy of treatments for solid tumors. Our laboratory encountered a high-grade, metastatic, neuroendocrine-like tumor from a pediatric patient that presented with a unique genetic profile...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quinn, Colin H., Beierle, Andee M., Williams, Adele P., Marayati, Raoud, Bownes, Laura V., Markert, Hooper R., Aye, Jamie M., Stewart, Jerry E., Mroczek-Musulman, Elizabeth, Crossman, David K., Yoon, Karina J., Beierle, Elizabeth A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086143/ https://www.ncbi.nlm.nih.gov/pubmed/33887553 http://dx.doi.org/10.1016/j.tranon.2021.101099

Ejemplares similares

CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells
por: Marayati, Raoud, et al.
Publicado: (2022)

EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth
por: Bownes, Laura V., et al.
Publicado: (2021)

Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma
por: Bownes, Laura V., et al.
Publicado: (2022)

PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells
por: Stafman, Laura L., et al.
Publicado: (2019)

Rapid Characterization of Solid Tumors Using Resonant Sensors
por: Beierle, Andee M., et al.
Publicado: (2022)

Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy
por: Quinn, Colin H., et al.
Publicado: (2022)

Serine-Threonine Kinase Receptor-Associated Protein (STRAP) Knockout Decreases the Malignant Phenotype in Neuroblastoma Cell Lines
por: Bownes, Laura V, et al.
Publicado: (2021)

Using 3D-bioprinted models to study pediatric neural crest-derived tumors
por: Quinn, Colin H, et al.
Publicado: (2023)

Immunotherapy in Pediatric Solid Tumors—A Systematic Review
por: Marayati, Raoud, et al.
Publicado: (2019)

UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts
por: Williams, Adele P., et al.
Publicado: (2019)

9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts
por: Marayati, Raoud, et al.
Publicado: (2020)

The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor
por: Aye, Jamie M., et al.
Publicado: (2019)

PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma
por: Marayati, Raoud, et al.
Publicado: (2021)

Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts
por: Stafman, Laura L., et al.
Publicado: (2019)

The Role of PIM Kinases in Pediatric Solid Tumors
por: Julson, Janet Rae, et al.
Publicado: (2022)

Artificial Tumor Microenvironments in Neuroblastoma
por: Quinn, Colin H., et al.
Publicado: (2021)

Adrenal extramedullary hematopoiesis in the setting of anti-Diego antibody and congenital dyserythropoietic anemia
por: Julson, Janet Rae, et al.
Publicado: (2022)

FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
por: Garner, Evan F., et al.
Publicado: (2018)

Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells()
por: Waters, Alicia M., et al.
Publicado: (2016)

Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma
por: Stafman, Laura L., et al.
Publicado: (2018)

Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth
por: Williams, Adele P., et al.
Publicado: (2018)

Radial glia require PDGFD/PDGFRß signaling in human but not mouse neocortex
por: Lui, Jan H., et al.
Publicado: (2014)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors
por: Megison, Michael L., et al.
Publicado: (2014)

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
por: Ye, Mingxiang, et al.
Publicado: (2016)

Pleuropulmonary blastoma in an adolescent
por: Bownes, Laura V., et al.
Publicado: (2020)

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
por: Wang, Yongfeng, et al.
Publicado: (2016)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma()()
por: Stafman, Laura L., et al.
Publicado: (2018)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma
por: Garner, Evan F., et al.
Publicado: (2015)

Cell Proliferation in Neuroblastoma
por: Stafman, Laura L., et al.
Publicado: (2016)

Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report
por: Zhu, Zhouyu, et al.
Publicado: (2017)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy
por: Friedman, Gregory K., et al.
Publicado: (2012)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

Invasive pulmonary aspergillosis presenting with tracheopleural fistula in a pediatric patient with a history of rhabdomyosarcoma
por: Khatun, Munteha, et al.
Publicado: (2023)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pju40elmav8qlog9rajc3nf18q